SEC Company Response from Voyager Therapeutics, Inc. (VYGR) (CIK 0001640266) (VYGR) — Nov 6, 2015
Voyager Therapeutics, Inc. (VYGR) (CIK 0001640266)
Date: Nov. 6, 2015 · CIK: 0001640266 · Accession: 0001104659-15-076741
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-207367
Letter
VIA EDGAR
November 6, 2015
United State Securities and Exchange Commission
Division of Corporation Finance
Mail Stop 4720
100 F Street, N.E.
Washington, D.C. 20549
Attn: Jeffrey P. Riedler, Assistant Director
Re: Voyager Therapeutics, Inc. (the “Company”)
Registration Statement on Form S-1 File No. 333-207367
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), and as representatives of the several underwriters of the Company’s proposed public offering of shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), we hereby join the Company’s request for acceleration of the effective date of the above-referenced Registration Statement, as amended, requesting effectiveness for 4:00 p.m. (ET) on November 10, 2015, or as soon thereafter as practicable.
Pursuant to Rule 460 of the Act, we wish to advise you that we have distributed approximately 755 copies of the Company’s preliminary prospectus relating to the Common Stock, dated October 30, 2015, through the date hereof to underwriters, dealers, institutions and others.
The undersigned, as representatives of the several underwriters, have complied and will continue to comply, and have been informed by the participating underwriters that they have complied and will continue to comply, with the provisions of Rule 15c2-8 of the Securities Exchange Act of 1934, as amended.
[Signature page follows]
Very truly yours,
COWEN AND COMPANY, LLC
Show Raw Text
CORRESP 1 filename1.htm VIA EDGAR November 6, 2015 United State Securities and Exchange Commission Division of Corporation Finance Mail Stop 4720 100 F Street, N.E. Washington, D.C. 20549 Attn: Jeffrey P. Riedler, Assistant Director Re: Voyager Therapeutics, Inc. (the “Company”) Registration Statement on Form S-1 File No. 333-207367 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), and as representatives of the several underwriters of the Company’s proposed public offering of shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), we hereby join the Company’s request for acceleration of the effective date of the above-referenced Registration Statement, as amended, requesting effectiveness for 4:00 p.m. (ET) on November 10, 2015, or as soon thereafter as practicable. Pursuant to Rule 460 of the Act, we wish to advise you that we have distributed approximately 755 copies of the Company’s preliminary prospectus relating to the Common Stock, dated October 30, 2015, through the date hereof to underwriters, dealers, institutions and others. The undersigned, as representatives of the several underwriters, have complied and will continue to comply, and have been informed by the participating underwriters that they have complied and will continue to comply, with the provisions of Rule 15c2-8 of the Securities Exchange Act of 1934, as amended. [Signature page follows] Very truly yours, COWEN AND COMPANY, LLC PIPER JAFFRAY & CO. Acting on their own behalf and as representatives of several underwriters By: COWEN AND COMPANY, LLC By: /s/ George Milstein Name: George Milstein Title: Co-head of Healthcare Investment Banking By: PIPER JAFFRAY & CO. By: /s/ Christie L. Christina Name: Christie L. Christina Title: Managing Director [Signature Page to Acceleration Request]